MedPath

Therapeutic efficacy of oral ketamine in obsessive compulsive disorder

Phase 4
Conditions
Health Condition 1: F42- Obsessive-compulsive disorder
Registration Number
CTRI/2021/09/036469
Lead Sponsor
GMC RH Patiala
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

Male and female patients aged 18-65 years with OCD diagnosed on DSM-5.

2. Patients who will be medically stable .

3. Patients who have given written informed consent.

Exclusion Criteria

1.History of chronic psychosis or drug induced psychosis of any kind.

2. Current DSM-5 diagnosis of drug abuse/dependence in the last six months and a negative drug screen at baseline.

3. Pregnant women, lactating mothers, surgically-sterile women or women who agree to continue using applicable birth control throughout the trial. All women of child-bearing potential must have a negative urine pregnancy test.

4. History of seizures, renal insufficiency or congestive heart failure.

5. History of Ketamine abuse/dependence or prior clinically significant adverse reaction to ketamine.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath